Literature DB >> 15917733

Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury.

Elena Napolitano1, Elie P Elovic, Adnan I Qureshi.   

Abstract

The sequelae of a traumatic or acquired brain injury may manifest itself in many ways that include decreased attention and arousal as well as cognitive, emotional and sensorimotor deficits. The discussion that follows will serve as a review of the use of stimulants in the management of patients with strokes or traumatic brain injury. The indications discussed include treating deficits in attention and arousal, as well as facilitating functional recovery. The literature cited has been derived from various research and clinical settings. After briefly reviewing, biochemistry and neuroanatomy, the paper discusses pertinent treatment issues such as the timing of initiation and discontinuation of stimulating medication with emphasis on the varied, current clinical practices. With the complexity of the various neurochemical processes that occur as a result of secondary brain damage, it would be impossible to review all potential stimulating agents in a single article. The authors' intent was to review the most commonly used neurostimulants, various intervention strategies, potential benefits and caveats and long-term outcomes with the use of these medications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917733

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

Review 1.  Medical therapies for concussion.

Authors:  William P Meehan
Journal:  Clin Sports Med       Date:  2011-01       Impact factor: 2.182

2.  Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats.

Authors:  Samuel S Shin; Eric R Bray; Cathy Q Zhang; C Edward Dixon
Journal:  Brain Res       Date:  2010-11-01       Impact factor: 3.252

Review 3.  Interventions for attention problems after pediatric traumatic brain injury: what is the evidence?

Authors:  Barynia Backeljauw; Brad G Kurowski
Journal:  PM R       Date:  2014-04-19       Impact factor: 2.298

Review 4.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  MicroRNA alteration in cerebrospinal fluid from comatose patients with traumatic brain injury after right median nerve stimulation.

Authors:  Ying Jia; Yi-Fan He; Ye Tian; Yuan-Zhi Wang; Rui-Ting Zhao; Xiao-Chun Li; Jian Sun; Ying-Sheng Wei; Shuo An; Heng-Jie Yuan; Chun-Xiao Wan; Rong-Cai Jiang
Journal:  Exp Brain Res       Date:  2022-08-07       Impact factor: 2.064

6.  Low-Molecular-Weight Fucoidan Attenuates Mitochondrial Dysfunction and Improves Neurological Outcome After Traumatic Brain Injury in Aged Mice: Involvement of Sirt3.

Authors:  Tao Wang; Mang Zhu; Zhong-Zheng He
Journal:  Cell Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.046

Review 7.  Psychiatric disturbances after traumatic brain injury: neurobehavioral and personality changes.

Authors:  Erin M Warriner; Diana Velikonja
Journal:  Curr Psychiatry Rep       Date:  2006-02       Impact factor: 5.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.